Neurostimulation Devices Market Report by Stimulation Type (Internal Stimulation, External Stimulation), Device Type (SCS (Spinal Cord Stimulation) Devices, DBS (Deep Brain Stimulation) Devices, SNS (Sacral Nerve Stimulation) Devices, VNS (Vagus Nerve Stimulation) Devices, GES (Gastric Electrical Stimulation) Devices, Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, and Others), Application (Pain Management, Epilepsy, Essential Tremors, Urinary and Fecal Incontinence, Depression, Dystonia, Parkinson’s Disease, and Others), End-User (Rehabilitation Centers, Hospitals, Medical Clinics, and Others), and Region 2024-2032

Neurostimulation Devices Market Report by Stimulation Type (Internal Stimulation, External Stimulation), Device Type (SCS (Spinal Cord Stimulation) Devices, DBS (Deep Brain Stimulation) Devices, SNS (Sacral Nerve Stimulation) Devices, VNS (Vagus Nerve Stimulation) Devices, GES (Gastric Electrical Stimulation) Devices, Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, and Others), Application (Pain Management, Epilepsy, Essential Tremors, Urinary and Fecal Incontinence, Depression, Dystonia, Parkinson’s Disease, and Others), End-User (Rehabilitation Centers, Hospitals, Medical Clinics, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A1892
Buy Now

Market Overview:

The global neurostimulation devices market size reached US$ 8.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.6 Billion by 2032, exhibiting a growth rate (CAGR) of 9.7% during 2024-2032. The growing aging population coupled with the rising healthcare expenditure, development of non-invasive or minimally invasive neurostimulation technologies, and improved reimbursement policies by government and private health insurers are some of the major factors propelling the market.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 8.7 Billion
Market Forecast in 2032
US$ 20.6 Billion
Market Growth Rate (2024-2032) 9.7%


Neurostimulation devices are advanced medical technologies designed to modulate and influence neural activity within the human body. These devices work by delivering electrical or magnetic impulses to specific regions of the nervous system, aiming to alleviate various neurological conditions and chronic disorders. They offer a promising non-invasive or minimally invasive therapeutic approach, enhancing the quality of life for patients and potentially opening up new avenues for treating various neurological disorders. The two primary types of neurostimulation devices are deep brain stimulation and spinal cord stimulation. DBS involves implanting electrodes into targeted brain areas to regulate abnormal neural signals and treat conditions such as Parkinson's disease, essential tremor, and dystonia.

The growing aging population is driving the global market. As the elderly population grows, the demand for neurostimulation devices to manage these conditions is likely to rise. Moreover, the development of non-invasive or minimally invasive neurostimulation technologies has expanded the potential patient pool, as these options often offer reduced risks and quicker recovery times compared to traditional surgical procedures. Besides, improved reimbursement policies by government and private health insurers in some regions have made neurostimulation treatments more accessible to patients, encouraging market growth. Also, ongoing research and clinical trials have provided additional evidence for the safety and efficacy of neurostimulation devices. Positive results from these studies have increased confidence in the technology among medical professionals and patients. Furthermore, the rising healthcare expenditure is supporting the growth of market solutions as neurostimulation devices offer a cost-effective approach to managing chronic conditions, which has driven their adoption.

Global Neurostimulation Devices Market Report

Neurostimulation Devices Market Trends/Drivers:

Increasing Prevalence of Neurological Disorders

Neurological conditions such as Parkinson's disease, epilepsy, chronic pain, and depression affect millions of people worldwide, leading to significant healthcare burdens. Neurostimulation devices offer a promising solution for patients who are refractory to conventional treatments or experience severe side effects. Deep brain stimulation (DBS) has demonstrated remarkable efficacy in managing movement disorders, such as Parkinson's disease, thereby augmenting the demand for these devices. Additionally, the escalating incidence of chronic pain, particularly due to aging populations and sedentary lifestyles, fuels the need for spinal cord stimulation (SCS) devices to provide pain relief without relying heavily on medications. As governments and healthcare organizations prioritize improved patient outcomes and seek innovative solutions, the demand for neurostimulation devices is expected to grow steadily.

Continual Advancements in Neurostimulation Technologies

Continuous research and development efforts have led to the creation of more sophisticated and targeted neurostimulation devices. Innovations include smaller and more precise electrodes, improved battery life, and the integration of closed-loop systems that can automatically adjust stimulation parameters based on real-time patient needs. These advancements translate to enhanced treatment outcomes, reduced side effects, and increased patient comfort. Moreover, the development of minimally invasive procedures for implanting neurostimulation devices has expanded their applicability to a broader patient population, making the treatments more accessible and appealing to both patients and healthcare providers. As technology continues to evolve, neurostimulation devices will likely become even more efficient and adaptable, further impelling their adoption and market penetration.

Growing Awareness and Acceptance of Neuromodulation Therapies

As more clinical evidence supports the effectiveness of neurostimulation devices in treating various neurological disorders, medical practitioners increasingly recommend these therapies to their patients. Additionally, patient advocacy groups and awareness campaigns have played a crucial role in educating individuals about the potential benefits of neurostimulation, leading to greater patient acceptance of these treatments. The success stories of patients who have experienced significant improvements in their quality of life through neurostimulation devices have further contributed to the positive perception of these therapies. As trust in neuromodulation grows, the demand for these devices is expected to increase, fuelling the market expansion. Furthermore, collaborations between healthcare organizations, researchers, and device manufacturers to spread awareness and ensure appropriate usage will contribute to the sustained growth of the neurostimulation devices market.

Neurostimulation Devices Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global neurostimulation devices market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on stimulation type, device type, application, and end-user.

Breakup by Stimulation Type:

  • Internal Stimulation
  • External Stimulation


The report has provided a detailed breakup and analysis of the market based on the stimulation type. This includes internal stimulation and external stimulation.

Internal stimulation devices form a significant segment within the neurostimulation market, characterized by their implantable nature. These devices are surgically placed within the body to deliver targeted electrical or magnetic stimulation directly to specific neural structures. The demand for internal stimulation devices is driven by their efficacy in managing complex neurological disorders that do not respond adequately to medications or other treatments. The ability to precisely target neural circuits while providing reversible and adjustable stimulation parameters enhances treatment outcomes, leading to improved patient quality of life.

On the other hand, external stimulation devices represent another substantial segment in the neurostimulation market, characterized by their non-invasive or minimally invasive nature. These devices are applied externally to the body's surface, delivering stimulation without the need for surgical implantation.

Breakup by Device Type:

  • SCS (Spinal Cord Stimulation) Devices
  • DBS (Deep Brain Stimulation) Devices
  • SNS (Sacral Nerve Stimulation) Devices
  • VNS (Vagus Nerve Stimulation) Devices
  • GES (Gastric Electrical Stimulation) Devices
  • Transcutaneous Electrical Nerve Stimulation Devices
  • Transcranial Magnetic Stimulation Devices
  • Others
     

SCS (spinal cord stimulation) dominates the market

The report has provided a detailed breakup and analysis of the market based on the device type. This includes spinal cord stimulation (SCS) devices, deep brain stimulation (DBS) devices, sacral nerve stimulation (SNS) devices, vagus nerve stimulation (VNS) devices, gastric electrical stimulation (GES) devices, transcutaneous electrical nerve stimulation devices, transcranial magnetic stimulation devices, and other. According to the report, SCS (spinal cord stimulation) devices represented the largest segment.

SCS involves the implantation of electrodes along the spinal cord, where electrical impulses are delivered to modulate pain signals and provide relief for chronic pain conditions. The minimally invasive nature of the procedure offers numerous benefits, including shorter recovery times and reduced risks compared to invasive surgeries. Additionally, the customizable nature of SCS allows for individualized programming to target specific pain areas, tailoring treatment to meet each patient's unique needs. Moreover, continual advancements in SCS technology have led to more sophisticated devices with improved battery life, smaller implants, and enhanced programming capabilities, providing greater patient comfort and long-term sustainability. The focus on patient-centered care and shared decision-making has led to an increased emphasis on personalized pain management plans. Spinal cord stimulation, with its individualized programming capabilities, aligns well with this patient-centric approach, fueling its adoption in pain management strategies.

Breakup by Application:

  • Pain Management
  • Epilepsy
  • Essential Tremors
  • Urinary and Fecal Incontinence
  • Depression
  • Dystonia
  • Parkinson’s Disease
  • Others
     

Pain management dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes pain management, epilepsy, essential tremors, urinary and fecal incontinence, depression, dystonia, Parkinson’s disease, and others. According to the report, pain management represents the largest segment.

Neurostimulation devices designed for pain management offer a promising alternative, particularly spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). These technologies work by delivering controlled electrical impulses to target nerves, modulating pain signals, and thereby reducing the perception of pain. Pain management through neurostimulation has demonstrated remarkable efficacy in various chronic pain conditions, including neuropathic pain, failed back surgery syndrome (FBSS), and complex regional pain syndrome (CRPS). Additionally, the advancements in neurostimulation technology have led to more personalized and precise pain management solutions, allowing for tailored treatment strategies based on individual patient needs.

Breakup by End-User:

  • Rehabilitation Centers
  • Hospitals
  • Medical Clinics
  • Others
     

Hospitals dominates the market

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes rehabilitation centers, hospitals, medical clinics, and others. According to the report, hospitals represented the largest segment.

Hospitals play a central role in the diagnosis, treatment, and management of various neurological and chronic disorders, which often require neurostimulation therapies as part of the treatment plan. Hospitals have access to multidisciplinary teams of medical professionals, including neurologists, neurosurgeons, pain specialists, and anesthesiologists, who collaborate to provide comprehensive care to patients requiring neurostimulation therapies. Additionally, they are equipped with state-of-the-art operating rooms and facilities that meet stringent regulatory standards, ensuring safe and effective implantation procedures. Furthermore, neurostimulation devices often require careful programming and adjustments to optimize treatment outcomes, and hospitals have the resources to support these ongoing patient management needs.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

North America exhibits a clear dominance, accounting for the largest neurostimulation devices market share.

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and Others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and Others), Latin America (Brazil, Mexico, and Others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a well-established healthcare infrastructure and is at the forefront of medical research and technological advancements. The presence of leading healthcare facilities, specialized neurology centers, and renowned research institutions fosters innovation and the adoption of cutting-edge neurostimulation technologies. Moreover, the region has a high prevalence of neurological disorders and chronic pain conditions, leading to a substantial demand for neurostimulation devices for effective management and treatment. The region's aging population, coupled with a growing awareness of neurostimulation therapies among patients and healthcare providers, further fuels market growth. Additionally, favorable reimbursement policies and regulatory frameworks in North America support the widespread adoption of neurostimulation devices.

Competitive Landscape:

Neurostimulation device manufacturers are heavily investing in research and development to enhance their existing products and develop new, innovative technologies. This involves conducting clinical trials, exploring new applications for neurostimulation, and improving the safety and efficacy of their devices. Moreover, companies are introducing new neurostimulation devices or release upgraded versions of existing ones. These launches aim to provide patients and healthcare professionals with state-of-the-art solutions that offer better outcomes and user experiences. Furthermore, companies actively seek to expand their market presence, both geographically and in terms of applications. They may pursue regulatory approvals in different regions, explore new therapeutic areas for neurostimulation, or target specific patient populations with unmet needs. Also, collaboration with other companies, research institutions, and healthcare organizations is common in the neurostimulation devices market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Biocontrol Medical
  • Boston Scientific Corporation
  • Cyberonics Inc.
  • Medtronic Inc.
  • Neuronetics Inc.
  • Neuropace Inc.
  • Neurosigma Inc.
  • Nevro Corporation
  • ST. Jude Medical Inc.
  • Synapse Biomedical Inc.

Recent Developments:

  • In April 2023, Synapse Biomedical Inc. received the approval for diaphragm pacing system, NeuRx DPS®. The NeuRx DPS® is a battery-powered device that delivers electrical stimulation via four percutaneous intramuscular electrodes implanted into the diaphragm with minimally invasive laparoscopy. It is intended for use in patients with stable SCI with stimulatable diaphragms, but who lack control of their diaphragms. The device is indicated to allow patients 18 years and older to breathe without the assistance of a mechanical ventilator for at least four continuous hours a day.
  • In March 2023, Nevro Corporation announced the Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain. It combines clinical inputs, such as pain relief and pain score, along with quality of life inputs, such as pain medication and activity level changes, to provide an individualized program setting for each patient.
  • In September 2022, Neuronetics Inc. launched Innovations to NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform. The TrakStar upgrades include a simplified interface to quickly sort and prioritize potential patients with ease. It also streamlines the patient journey by bridging our proprietary PHQ-10 platform with our HIPAA-compliant TrakStar patient data management system making it easier to identify new patients and those needing re-treatment.

Neurostimulation Devices Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Stimulation Type
  • Device Type
  • Application
  • End-User
  • Region
Stimulation Types Covered Internal Stimulation, External Stimulation
Device Types Covered Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation (DBS) Devices, Sacral Nerve Stimulation (SNS) Devices, Vagus Nerve Stimulation (VNS) Devices, Gastric Electrical Stimulation (GES) Devices, Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, Others
Applications Covered Pain Management, Epilepsy, Essential Tremors, Urinary and Fecal Incontinence, Depression, Dystonia, Parkinson’s Disease, Others
End-Users Covered Rehabilitation Centers, Hospitals, Medical Clinics, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Biocontrol Medical, Boston Scientific Corporation, Cyberonics Inc., Medtronic Inc., Neuronetics Inc., Neuropace Inc., Neurosigma Inc., Nevro Corporation, ST. Jude Medical Inc., Synapse Biomedical Inc. etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the neurostimulation devices market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global neurostimulation devices market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the neurostimulation devices industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global neurostimulation devices market was valued at US$ 8.7 Billion in 2023.

We expect the global neurostimulation devices market to exhibit a CAGR of 9.7% during 2024-2032.

The rising instances of neurological disorders, along with the growing application of neurostimulation devices to aid in the treatment of movement disorders, chronic pain, and epilepsy, are primarily driving the global neurostimulation devices market.

The sudden outbreak of the COVID-19 pandemic had led to postponement of elective procedures for neural prosthetics, hearing aid, artificial vision, etc., to reduce the risk of the coronavirus infection upon interaction with medical equipment, thereby limiting the demand for neurostimulation devices.

Based on the device type, the global neurostimulation devices market can be categorized into SCS (Spinal Cord Stimulation) devices, DBS (Deep Brain Stimulation) devices, SNS (Sacral Nerve Stimulation) devices, VNS (Vagus Nerve Stimulation) devices, GES (Gastric Electrical Stimulation) devices, transcutaneous electrical nerve stimulation devices, transcranial magnetic stimulation devices, and others. Currently, SCS (Spinal Cord Stimulation) devices exhibit clear dominance in the market.

Based on the application, the global neurostimulation devices market has been segmented into pain management, epilepsy, essential tremors, urinary and fecal incontinence, depression, dystonia, Parkinson’s disease, and others. Among these, pain management represents the largest market share.

Based on the end-user, the global neurostimulation devices market can be bifurcated into rehabilitation centers, hospitals, medical clinics, and others. Currently, hospitals account for the majority of the total market share.

On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.

Some of the major players in the global neurostimulation devices market include Biocontrol Medical, Boston Scientific Corporation, Cyberonics Inc., Medtronic Inc., Neuronetics Inc., Neuropace Inc., Neurosigma Inc., Nevro Corporation, ST. Jude Medical Inc., Synapse Biomedical Inc., etc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Neurostimulation Devices Market Report by Stimulation Type (Internal Stimulation, External Stimulation), Device Type (SCS (Spinal Cord Stimulation) Devices, DBS (Deep Brain Stimulation) Devices, SNS (Sacral Nerve Stimulation) Devices, VNS (Vagus Nerve Stimulation) Devices, GES (Gastric Electrical Stimulation) Devices, Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, and Others), Application (Pain Management, Epilepsy, Essential Tremors, Urinary and Fecal Incontinence, Depression, Dystonia, Parkinson’s Disease, and Others), End-User (Rehabilitation Centers, Hospitals, Medical Clinics, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More